{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:04:42Z","timestamp":1769749482095,"version":"3.49.0"},"reference-count":61,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Department for Environment, Food, and Rural Affairs (Defra)","award":["SE0426"],"award-info":[{"award-number":["SE0426"]}]},{"name":"UK Department for Environment, Food, and Rural Affairs (Defra)","award":["SE0431"],"award-info":[{"award-number":["SE0431"]}]},{"name":"UK Department for Environment, Food, and Rural Affairs (Defra)","award":["774078"],"award-info":[{"award-number":["774078"]}]},{"name":"UK Department for Environment, Food, and Rural Affairs (Defra)","award":["760331"],"award-info":[{"award-number":["760331"]}]},{"name":"APHA","award":["SE0426"],"award-info":[{"award-number":["SE0426"]}]},{"name":"APHA","award":["SE0431"],"award-info":[{"award-number":["SE0431"]}]},{"name":"APHA","award":["774078"],"award-info":[{"award-number":["774078"]}]},{"name":"APHA","award":["760331"],"award-info":[{"award-number":["760331"]}]},{"name":"Hotung Charitable Foundation","award":["SE0426"],"award-info":[{"award-number":["SE0426"]}]},{"name":"Hotung Charitable Foundation","award":["SE0431"],"award-info":[{"award-number":["SE0431"]}]},{"name":"Hotung Charitable Foundation","award":["774078"],"award-info":[{"award-number":["774078"]}]},{"name":"Hotung Charitable Foundation","award":["760331"],"award-info":[{"award-number":["760331"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Rabies virus (RABV) causes possibly the oldest disease and is responsible for an estimated &gt;59,000 human fatalities\/year. Post exposure prophylaxis (PEP), the administration of vaccine and rabies immunoglobulin, is a highly effective tool which is frequently unavailable in RABV endemic areas. Furthermore, due to the constraints of the blood-brain barrier, current PEP regimes are ineffective after the onset of clinical symptoms which invariably result in death. To circumvent this barrier, a live-attenuated recombinant RABV expressing a highly RABV-neutralising scFv antibody (62-71-3) linked to the fluorescent marker mCherry was designed. Once rescued, the resulting construct (named RABV-62scFv) was grown to high titres, its growth and cellular dissemination kinetics characterised, and the functionality of the recombinant 62-71-3 scFv assessed. Encouraging scFv production and subsequent virus neutralisation results demonstrate the potential for development of a therapeutic live-attenuated virus-based post-infection treatment (PIT) for RABV infection.<\/jats:p>","DOI":"10.3390\/v15081674","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:14:40Z","timestamp":1690881280000},"page":"1674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies"],"prefix":"10.3390","volume":"15","author":[{"given":"Samuel P.","family":"Smith","sequence":"first","affiliation":[{"name":"Wildlife Zoonoses and Vector-Borne Diseases Research Group, Animal and Plant Health Agency (APHA), Weybridge, London KT15 3NB, UK"},{"name":"Institute for Infection and Immunity, St. George\u2019s Hospital Medical School, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-9596","authenticated-orcid":false,"given":"Rebecca","family":"Shipley","sequence":"additional","affiliation":[{"name":"Wildlife Zoonoses and Vector-Borne Diseases Research Group, Animal and Plant Health Agency (APHA), Weybridge, London KT15 3NB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Drake","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St. George\u2019s Hospital Medical School, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3243-6154","authenticated-orcid":false,"given":"Anthony R.","family":"Fooks","sequence":"additional","affiliation":[{"name":"Wildlife Zoonoses and Vector-Borne Diseases Research Group, Animal and Plant Health Agency (APHA), Weybridge, London KT15 3NB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St. George\u2019s Hospital Medical School, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-9825","authenticated-orcid":false,"given":"Ashley C.","family":"Banyard","sequence":"additional","affiliation":[{"name":"Wildlife Zoonoses and Vector-Borne Diseases Research Group, Animal and Plant Health Agency (APHA), Weybridge, London KT15 3NB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"ref_1","first-page":"3","article-title":"Development in Immunoprophylaxis against Rabies for Animals and Humans","volume":"2","author":"Nandi","year":"2010","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., and Cleaveland, S. (2015). Global Alliance for Rabies Control Partners for Rabies, P. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop Dis., 9.","DOI":"10.1371\/journal.pntd.0003786"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0042-6822(90)90433-R","article-title":"Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19","volume":"175","author":"Conzelmann","year":"1990","journal-title":"Virology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02017-19","article-title":"Development of a Highly Effective African Swine Fever Virus Vaccine by Deletion of the I177L Gene Results in Sterile Immunity against the Current Epidemic Eurasia Strain","volume":"94","author":"Borca","year":"2020","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Calvelage, S., Tammiranta, N., Nokireki, T., Gadd, T., Eggerbauer, E., Zaeck, L.M., Potratz, M., Wylezich, C., Hoper, D., and Muller, T. (2021). Genetic and Antigenetic Characterization of the Novel Kotalahti Bat Lyssavirus (KBLV). Viruses, 13.","DOI":"10.3390\/v13010069"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.20506\/rst.37.2.2833","article-title":"Cost-benefit analysis of controlling rabies: Placing economics at the heart of rabies control to focus political will","volume":"37","author":"Shwiff","year":"2018","journal-title":"Rev. Sci. Tech."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.03.023","article-title":"Successful strategies implemented towards the elimination of canine rabies in the Western Hemisphere","volume":"143","author":"Escobar","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20120142","DOI":"10.1098\/rstb.2012.0142","article-title":"The elimination of fox rabies from Europe: Determinants of success and lessons for the future","volume":"368","author":"Freuling","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_10","first-page":"361","article-title":"Global epidemiology of canine rabies: Past, present, and future prospects","volume":"6","author":"Taylor","year":"2015","journal-title":"Vet. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.4049\/jimmunol.1501274","article-title":"T-bet Is Required for the Rapid Clearance of Attenuated Rabies Virus from Central Nervous System Tissue","volume":"195","author":"Lebrun","year":"2015","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hooper, D.C., Phares, T.W., Fabis, M.J., and Roy, A. (2009). The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000535"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/fvl.10.88","article-title":"Therapeutic immune clearance of rabies virus from the CNS","volume":"6","author":"Hooper","year":"2011","journal-title":"Future Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1128\/JVI.72.5.3711-3719.1998","article-title":"Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system","volume":"72","author":"Hooper","year":"1998","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virusres.2018.02.012","article-title":"Revisiting rabies virus neutralizing antibodies through infecting BALB\/c mice with live rabies virus","volume":"248","author":"Qin","year":"2018","journal-title":"Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Damodar, T., Mani, R.S., and Prathyusha, P.V. (2019). Utility of rabies neutralizing antibody detection in cerebrospinal fluid and serum for ante-mortem diagnosis of human rabies. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007128"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gnanadurai, C.W., Zhou, M., He, W., Leyson, C.M., Huang, C.T., Salyards, G., Harvey, S.B., Chen, Z., He, B., and Yang, Y. (2013). Presence of virus neutralizing antibodies in cerebral spinal fluid correlates with non-lethal rabies in dogs. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002375"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Realegeno, S., Niezgoda, M., Yager, P.A., Kumar, A., Hoque, L., Orciari, L., Sambhara, S., Olson, V.A., and Satheshkumar, P.S. (2018). An ELISA-based method for detection of rabies virus nucleoprotein-specific antibodies in human antemortem samples. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207009"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1128\/JVI.00710-07","article-title":"Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier","volume":"81","author":"Roy","year":"2007","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1423-0127-19-61","article-title":"Sufficient virus-neutralizing antibody in the central nerve system improves the survival of rabid rats","volume":"19","author":"Liao","year":"2012","journal-title":"J. Biomed. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1073\/pnas.89.15.7252","article-title":"Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system","volume":"89","author":"Dietzschold","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.4049\/jimmunol.176.12.7666","article-title":"Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system","volume":"176","author":"Phares","year":"2006","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1099\/jgv.0.000998","article-title":"Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses","volume":"99","author":"Evans","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_24","unstructured":"WHO World Health Organization (2002). WHO Consultation on a Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment, WHO."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1096\/fj.12-219964","article-title":"Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans","volume":"27","author":"Both","year":"2013","journal-title":"FASEB J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Muller, T., Dietzschold, B., Ertl, H., Fooks, A.R., Freuling, C., Fehlner-Gardiner, C., Kliemt, J., Meslin, F.X., Franka, R., and Rupprecht, C.E. (2009). Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.01.025","article-title":"Monoclonal antibodies for prophylactic and therapeutic use against viral infections","volume":"31","author":"Both","year":"2013","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/infdis\/jiu085","article-title":"Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody","volume":"210","author":"Teh","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0014-5793(04)00150-4","article-title":"Generation of Arabidopsis thaliana plants with complex N-glycans lacking beta1,2-linked xylose and core alpha1,3-linked fucose","volume":"561","author":"Strasser","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/hv.7.3.14266","article-title":"Emerging antibody products and Nicotiana manufacturing","volume":"7","author":"Whaley","year":"2011","journal-title":"Hum. Vaccin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1128\/JVI.01153-10","article-title":"Quantifying antigenic relationships among the lyssaviruses","volume":"84","author":"Horton","year":"2010","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fooks, A.R., Shipley, R., Markotter, W., Tordo, N., Freuling, C.M., Muller, T., McElhinney, L.M., Banyard, A.C., and Rupprecht, C.E. (2021). Renewed Public Health Threat from Emerging Lyssaviruses. Viruses, 13.","DOI":"10.3390\/v13091769"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20200352","DOI":"10.1590\/0037-8682-0352-2020","article-title":"Comparing clinical protocols for the treatment of human rabies: The Milwaukee protocol and the Brazilian protocol (Recife)","volume":"53","author":"Ledesma","year":"2020","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1099\/jgv.0.001269","article-title":"Trying to treat the untreatable: Experimental approaches to clear rabies virus infection from the CNS","volume":"100","author":"Smith","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e12628","DOI":"10.15252\/emmm.202012628","article-title":"A combination of two human monoclonal antibodies cures symptomatic rabies","volume":"12","author":"Sonthonnax","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","article-title":"Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response","volume":"76","author":"Faber","year":"2002","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1073\/pnas.0905640106","article-title":"Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus","volume":"106","author":"Faber","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","first-page":"219","article-title":"Protective efficacy of live attenuated rabies virus against Lethal Challenged Virus Strain (CVS-11) infection in the Central Nervous System (CNS) of mice","volume":"165","author":"Huang","year":"2014","journal-title":"Viruses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4149\/av_2015_02_117","article-title":"Efficiency of live attenuated and inactivated rabies viruses in prophylactic and post exposure vaccination against the street virus strain","volume":"59","author":"Huang","year":"2015","journal-title":"Acta Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhang, G., Wen, Y., Yang, S., Xia, X., and Fu, Z.F. (2011). Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025414"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kgaladi, J., Faber, M., Dietzschold, B., Nel, L.H., and Markotter, W. (2017). Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine. Trop. Med. Infect. Dis., 2.","DOI":"10.3390\/tropicalmed2030037"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16328","DOI":"10.1073\/pnas.0407289101","article-title":"Identification of viral genomic elements responsible for rabies virus neuroinvasiveness","volume":"101","author":"Faber","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1099\/vir.0.048827-0","article-title":"Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein","volume":"94","author":"Marston","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.vaccine.2005.03.037","article-title":"Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses","volume":"23","author":"Brookes","year":"2005","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2045-8118-10-33","article-title":"Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC\/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies","volume":"10","author":"Eigenmann","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"ref_47","first-page":"e58900","article-title":"Lucifer Yellow-A Robust Paracellular Permeability Marker in a Cell Model of the Human Blood-brain Barrier","volume":"150","author":"Zhao","year":"2019","journal-title":"J. Vis. Exp."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1067","DOI":"10.1016\/j.ijid.2010.07.004","article-title":"Utility of human embryonic kidney cell line HEK-293 for rapid isolation of fixed and street rabies viruses: Comparison with Neuro-2a and BHK-21 cell lines","volume":"14","author":"Madhusudana","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/jcm.27.11.2522-2528.1989","article-title":"Development and evaluation of an in vitro virus isolation procedure as a replacement for the mouse inoculation test in rabies diagnosis","volume":"27","author":"Rudd","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15405","DOI":"10.1128\/JVI.79.24.15405-15416.2005","article-title":"Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice","volume":"79","author":"Faber","year":"2005","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/pbi.12719","article-title":"Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device","volume":"15","author":"Phoolcharoen","year":"2017","journal-title":"Plant Biotechnol. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1128\/JVI.74.16.7261-7269.2000","article-title":"Differential transcription attenuation of rabies virus genes by intergenic regions: Generation of recombinant viruses overexpressing the polymerase gene","volume":"74","author":"Finke","year":"2000","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"632957","DOI":"10.3389\/fcell.2020.632957","article-title":"Change in the Single Amino Acid Site 83 in Rabies Virus Glycoprotein Enhances the BBB Permeability and Reduces Viral Pathogenicity","volume":"8","author":"Li","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JVI.02327-07","article-title":"The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread","volume":"82","author":"Pulmanausahakul","year":"2008","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1002\/cpmc.105","article-title":"Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2","volume":"57","author":"Mendoza","year":"2020","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-0716-0203-4_16","article-title":"The Propagation and Quantification of Two Emerging Oncolytic Viruses: Vesicular Stomatitis (VSV) and Zika (ZIKV)","volume":"2097","author":"Means","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_57","first-page":"e52065","article-title":"Viral concentration determination through plaque assays: Using traditional and novel overlay systems","volume":"93","author":"Baer","year":"2014","journal-title":"J. Vis. Exp."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26100","DOI":"10.1038\/srep26100","article-title":"Molecular determinants of plaque size as an indicator of dengue virus attenuation","volume":"6","author":"Goh","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fmicb.2017.00120","article-title":"Phenotypic Consequences In vivo and In vitro of Rearranging the P Gene of RABV HEP-Flury","volume":"8","author":"Mei","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Luo, J., Zhang, Y., Zhang, Q., Wu, Y., Zhang, B., Mo, M., Tian, Q., Zhao, J., Mei, M., and Guo, X. (2019). The Deoptimization of Rabies Virus Matrix Protein Impacts Viral Transcription and Replication. Viruses, 12.","DOI":"10.3390\/v12010004"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1128\/JVI.00809-16","article-title":"Roles of the Rabies Virus Phosphoprotein Isoforms in Pathogenesis","volume":"90","author":"Okada","year":"2016","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:23:34Z","timestamp":1760127814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["v15081674"],"URL":"https:\/\/doi.org\/10.3390\/v15081674","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}